Literature DB >> 21978644

Administration of resveratrol: What formulation solutions to bioavailability limitations?

A Amri1, J C Chaumeil, S Sfar, C Charrueau.   

Abstract

Resveratrol (3,5,4'-trihydroxystilbene), a naturally occurring polyphenol, has attracted considerable interest for its beneficial potentials for human health, which include anti-oxidant, anti-inflammatory, cardioprotective and anti-tumor activities. However, the in vivo biological effects of resveratrol appear strongly limited by its low bioavailability, which is a barrier to the development of therapeutic applications. In this context, an increasing number of recent studies have aimed at designing novel resveratrol formulations to overcome its poor solubility, limited stability, high metabolization and weak bioavailability. This review outlines physicochemical and pharmacokinetic limitations to resveratrol bioavailability, describes formulations tested for resveratrol administration, controlled release and targeting, and identifies future opportunities for resveratrol delivery. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978644     DOI: 10.1016/j.jconrel.2011.09.083

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  123 in total

Review 1.  Resveratrol biosynthesis: plant metabolic engineering for nutritional improvement of food.

Authors:  Giovanna Giovinazzo; Ilaria Ingrosso; Annalisa Paradiso; Laura De Gara; Angelo Santino
Journal:  Plant Foods Hum Nutr       Date:  2012-09       Impact factor: 3.921

2.  Preparation and in-vitro/in-vivo characterization of trans-resveratrol nanocrystals for oral administration.

Authors:  Sandeep K Singh; Vishal Makadia; Shweta Sharma; Mamunur Rashid; Sudhir Shahi; Prabhat R Mishra; Mohammed Wahajuddin; Jiaur R Gayen
Journal:  Drug Deliv Transl Res       Date:  2017-06       Impact factor: 4.617

Review 3.  Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases.

Authors:  Yang Sun; Tuo Yang; Rehana K Leak; Jun Chen; Feng Zhang
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

4.  Effect of lipolysis on drug release from self-microemulsifying drug delivery systems (SMEDDS) with different core/shell drug location.

Authors:  Jianbin Zhang; Yan Lv; Shan Zhao; Bing Wang; Mingqian Tan; Hongguo Xie; Guojun Lv; Xiaojun Ma
Journal:  AAPS PharmSciTech       Date:  2014-02-20       Impact factor: 3.246

Review 5.  Role of dietary phenols in mitigating microglia-mediated neuroinflammation.

Authors:  Parakalan Rangarajan; Aparna Karthikeyan; S T Dheen
Journal:  Neuromolecular Med       Date:  2016-07-27       Impact factor: 3.843

6.  Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice.

Authors:  Renzo Mancuso; Jaume del Valle; Laura Modol; Anna Martinez; Ana B Granado-Serrano; Omar Ramirez-Núñez; Mercé Pallás; Manel Portero-Otin; Rosario Osta; Xavier Navarro
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 7.  Resveratrol supplementation: Where are we now and where should we go?

Authors:  Marta G Novelle; Devin Wahl; Carlos Diéguez; Michel Bernier; Rafael de Cabo
Journal:  Ageing Res Rev       Date:  2015-01-24       Impact factor: 10.895

8.  Immunotoxicity studies of trans-resveratrol in male B6C3F1/N mice.

Authors:  Madelyn C Huang; Kimber L White; Susan A Elmore; Tai L Guo; Dori Germolec
Journal:  J Immunotoxicol       Date:  2020-12       Impact factor: 3.000

Review 9.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules.

Authors:  Rudimar L Frozza; Andressa Bernardi; Juliana B Hoppe; André B Meneghetti; Aline Matté; Ana M O Battastini; Adriana R Pohlmann; Sílvia S Guterres; Christianne Salbego
Journal:  Mol Neurobiol       Date:  2013-01-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.